Is Stacking Biologics Safe if You Have Ulcerative Colitis?
Published on May 27, 2026
ON THIS PAGE
ON THIS PAGE
Biologic stacking in ulcerative colitis (UC) treatment, also called dual therapy, means taking two or more advanced therapies at the same time, such as two biologics, or a biologic and a small molecule drug. Dual therapy may be necessary in moderate to severe UC that doesn’t respond adequately to one advanced treatment.
Research shows that up to 4 in 10 people with an inflammatory bowel disease (IBD) like UC don’t respond to anti-tumor necrosis factor (anti-TNF) alpha drugs, a type of biologic often used as a first option for advanced therapy. And 23 to 46 percent of those who get better on a single anti-TNF alpha drug have symptoms that return.
Although it’s a newer treatment option that still needs more research on safety and efficacy, more providers are considering stacking advanced therapies as a solution when one medication isn’t effective.
What Does ‘Stacking Biologics’ Mean?
Inflammation can develop along several different pathways in the body to cause UC symptoms, just like you can get to a destination by more than one road. And biologic medications treat UC inflammation by affecting a number of different pathways.
“Biologic stacking refers to the combination of [advanced therapies] that work together to reduce inflammation in the colon,” says Eliane Nguyen, PharmD, a clinical pharmacist specialist at VCU Health Medical Center in Richmond, Virginia. This combination usually includes two biologics or a biologic and a small molecule drug that target different causes of the inflammation process.
For example, TNF inhibitors like infliximab (Remicade) block an inflammation-causing protein called tumor necrosis factor (TNF) alpha. Using dual therapy, providers can add other medications, like the biologic vedolizumab (Entyvio), which blocks certain immune cells from adhering to a molecule found on cells in your intestines and causing inflammation.
By taking these drugs together, they can not only block inflammation from two different causes, but they may also help each other work better.
Is Stacking Biologics Safe for Ulcerative Colitis?
Experts are still studying the effects of stacking biologics — both positive and negative. For example, the DUET-CD clinical trial is assessing the safety and effectiveness of dual therapy using guselkumab (Tremfya) and golimumab (Simponi) in people with moderate to severe UC.
In already published studies, the most common side effects of dual therapy include:
- Headache
- Upper respiratory tract infection
- Low levels of red blood cells (anemia)
- The common cold
- Low levels of white blood cells (neutropenia)
- Fever
In one study of 214 people with UC, those taking two biologics had about the same number of side effects (or fewer) than those who took only one.
People often think that using more than one advanced therapy will cause extra side effects, says Stephen Bickston, MD, the associate chief of gastroenterology at VCU Medical Center in Richmond, Virginia. “[But] the experience we have had at our institution and what is published in the literature suggests that these combinations are generally well tolerated.”
“As with any [advanced] treatment, whether used alone or in combination, regular monitoring is important so that any side effects can be caught early,” says Dr. Nguyen, who adds that larger, long-term studies are still needed to confirm the efficacy and safety of biologic stacking.
Should You Consider Stacking Biologics for Ulcerative Colitis?
Your gastroenterologist will take several factors into account before they recommend combining advanced therapies. “Disease severity, multiple prior biologic failures, and concurrent extraintestinal manifestations or other immune-related diseases are all considered when deciding to initiate dual [advanced] treatment,” says Nguyen.
When Your Ulcerative Colitis Hasn’t Responded Well to Treatment
“Patients with long-standing, hard-to-manage disease rise to the top,” says Dr. Bickston. This means if other treatments haven’t worked well to decrease UC symptoms and promote intestinal healing, dual therapy may be a potential next step.
When Surgery Isn’t an Option
Some people have surgery to remove the part of their colon affected by UC, or the whole colon. “But not all patients want surgery,” says Bickston. “Some also have conditions that make them unfit for surgery, so maximizing medical therapy is vital.” In these cases, biologic stacking may be a good option.
When You’re Having Symptoms Outside Your Colon
Dual therapy may also work well for people who have extraintestinal manifestations of UC — symptoms that affect areas of the body outside the colon. These complications can include symptoms or conditions that affect the joints, skin, eyes, blood, and bones, as well as organs like your kidneys and liver.
Whether You’re Able to Access the Medication
Even if you’re a good candidate for dual biologic therapy, expense can be a barrier. Nearly all insurance providers require proof that you have tried other UC treatments that failed before they will approve a biologic therapy at all, much less two.
Biologic medications are expensive in the United States — they can cost many thousands of dollars per year. And many insurance companies haven’t updated their clinical guidelines in years, so they may not represent current standards of care. To find out if your insurer will cover the cost of two advanced therapies, you can check your coverage details or call their customer service number to find out what they require for coverage.
The Takeaway
- Stacking biologics (dual therapy), a treatment option for ulcerative colitis, involves taking two biologic medications at once, or a biologic and a small molecule drug in combination.
- Dual therapy has some risk of side effects, and the most common include headache, fever, infections, and anemia.
- Your gastroenterologist can help you understand whether biologic stacking is a good treatment option for you.
Resources We Trust
- Mayo Clinic: Medicines That Treat Ulcerative Colitis
- Cleveland Clinic: What Are Biologics and Small Molecules for Ulcerative Colitis?
- University of Chicago Medicine: Biologics and Inflammatory Bowel Disease (IBD)
- Crohn’s & Colitis Foundation: Medication Options for Ulcerative Colitis
- Crohn’s and Colitis Canada: Treatment and Medication: Biotherapies
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
- Fabisiak A et al. Advancements in Dual Biologic Therapy for Inflammatory Bowel Diseases: Efficacy, Safety, and Future Directions. Therapeutic Advances in Gastroenterology. January 2, 2025.
- Altieri G et al. Dual Therapy in Inflammatory Bowel Disease. Biomolecules. February 3, 2025.
- Bu S et al. Ulcerative Colitis: Advances in Pathogenesis, Biomarkers, and Therapeutic Strategies. Pharmacogenomics and Personalized Medicine. September 5, 2025.
- TNF (Tumor Necrosis Factor) Inhibitors. Cleveland Clinic. July 2, 2025.
- Pudipeddi A et al. Vedolizumab in Inflammatory Bowel Disease: Pharmacokinetics and the Role of Immunomodulator Co-Therapy. Therapeutic Advances in Gastroenterology. January 19, 2026.
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC). Clinicaltrials.gov. April 13, 2026.
- Feagan BG et al. Guselkumab Plus Golimumab Combination Therapy Versus Guselkumab or Golimumab Monotherapy in Patients With Ulcerative Colitis (VEGA): A Randomised, Double-Blind, Controlled, Phase 2, Proof-Of-Concept Trial. The Lancet Gastroenterology & Hepatology. April 2023.
- Lynch WD et al. Ulcerative Colitis. StatPearls. June 5, 2023.
- Altieri G et al. Dual Therapy in Inflammatory Bowel Disease. Biomolecules. February 3, 2025.
- Extraintestinal Complications of IBD. Crohn's & Colitis Foundation.
- The Real Cost of Biologic Drugs. American Partnership for Eosinophilic Disorders (APFED). November 22, 2024.
- Zisman E et al. Insurance Denial of Biologic Therapy is Associated With Reduced Remission Rates in Inflammatory Bowel Disease Patients. Gastro Hep Advances. February 27, 2025.
Meet Our Experts
Ira Daniel Breite, MD
Medical Reviewer
Ira Daniel Breite, MD, is a board-certified internist and gastroenterologist. He is an associate professor at the Icahn School of Medicine at Mount Sinai, where he also sees patien...
Abby McCoy, RN
Author
Abby McCoy is an experienced registered nurse who has worked with adults and pediatric patients encompassing trauma, orthopedics, home care, transplant, and case management. She is...